Loading
CT
Chinook Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Thomas Dolca, was filed 06 Sept 2022.
Chinook Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Chinook Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Chinook Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 11 August 2023.
Over the whole record (from 2015), the tally stands at 24 purchases and 239 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
617
Thresholds
n/a
Buy Volume
€35M
24 ops. · all time
Sell Volume
€75M
239 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$5.3M
Net income-US$161.8M-3065.7% margin
Last declaration on 11 August 2023
Declarations617 total
2,105,107 sharesCommon StockSEC:0001209191-23-045415:1
719,104 sharesCommon StockSEC:0001209191-23-045415:2
210,996 sharesCommon StockSEC:0001209191-23-045415:3
5,161,888 sharesCommon StockSEC:0001209191-23-045411:1
13,300 sharesCommon StockSEC:0001209191-23-045430:0
3,300 sharesCommon StockSEC:0001209191-23-045422:0
150,777 sharesCommon StockSEC:0001209191-23-045418:0
1,275 sharesCommon StockSEC:0001209191-23-045428:0
447,013 sharesCommon StockSEC:0001209191-23-045415:0
301,138 sharesCommon StockSEC:0001209191-23-045417:0
19,157 sharesCommon StockSEC:0001209191-23-045424:0
39,371 sharesCommon StockSEC:0001209191-23-045414:0
3,300 sharesCommon StockSEC:0001209191-23-045411:0
23,643 sharesCommon StockSEC:0001209191-23-045420:0
1,168 shares@ US$39.034.0% of flowCommon StockSEC:0001209191-23-044071:1
3,333 sharesCommon StockSEC:0001209191-23-044071:0
1,155 shares@ US$23.3068.0% of flowCommon StockSEC:0001209191-23-033191:1
3,300 sharesCommon StockSEC:0001209191-23-033187:0
3,300 sharesCommon StockSEC:0001209191-23-033190:0
3,300 sharesCommon StockSEC:0001209191-23-033189:0
3,300 sharesCommon StockSEC:0001209191-23-033191:0
3,300 sharesCommon StockSEC:0001209191-23-033188:0
3,300 sharesCommon StockSEC:0001209191-23-033186:0
25,000 shares@ US$0.424.5% of flowCommon StockSEC:0001209191-23-025720:0
23,800 shares@ US$21.576819.0% of flowCommon StockSEC:0001209191-23-025720:1
25 of 617 declarations
About Chinook Therapeutics, Inc.
CHINOOK THERAPEUTICS, INC. (ticker KDNY) was a United States biopharmaceutical company focused on kidney disease and historically listed on Nasdaq in the US market (NYSE/NASDAQ context). Headquartered in Seattle, Washington, United States, Chinook was founded in 2019 by a team with deep biotech and venture capital experience, and it was built around a clear thesis: developing precision medicines for rare, severe chronic kidney diseases where treatment options remain limited and unmet medical need is high. Its business profile was that of a clinical-stage company rather than a commercial pharmaceutical group, with enterprise value driven primarily by pipeline progress, clinical data readouts, and regulatory milestones. ([cbinsights.com](https://www.cbinsights.com/company/chinook-therapeutics?utm_source=openai))
The company’s core mission was to discover, develop, and commercialize therapies for nephrology indications such as IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), Alport syndrome, primary hyperoxaluria, and other rare chronic kidney disorders. Chinook’s platform combined single-cell RNA sequencing, human-derived organoids, and translational models to identify differentiated mechanisms of action in kidney disease biology. Key clinical and preclinical programs included atrasentan, BION-1301, and CHK-336, reflecting a pipeline strategy centered on specialized, high-unmet-need indications rather than broad primary care markets. ([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/30/2342968/35377/en/chinook-therapeutics-announces-formation-of-sanreno-therapeutics-a-joint-venture-to-develop-kidney-disease-therapies-in-china.html?utm_source=openai))
Read moreShow less
In competitive terms, Chinook aimed to stand out in precision nephrology, a relatively concentrated area where scientific differentiation and strong clinical evidence are critical. Its geographic footprint was largely US-based, with Seattle as its operating center, but it also pursued international expansion through SanReno, a joint venture created to develop, manufacture, and commercialize kidney disease therapies in selected Asian markets. That structure suggested an ambition to build a broader regional presence beyond the domestic US market. ([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/30/2342968/35377/en/chinook-therapeutics-announces-formation-of-sanreno-therapeutics-a-joint-venture-to-develop-kidney-disease-therapies-in-china.html?utm_source=openai))
The most important recent development was Chinook’s acquisition by Novartis in 2023. SEC filings and exchange notices show that shareholders approved the merger and that the company’s KDNY securities were converted as part of the transaction, after which Chinook ceased to function as an independent listed issuer. For investors, Chinook should therefore be viewed as an acquired biotech asset whose pipeline value was ultimately recognized through a strategic takeout rather than as an ongoing standalone public company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1435049/000119312523164896/d511815ddefa14a.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
